63. Idiopathic thrombocytopenic purpura Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
Drugs and their primary sponsors and trial info
10-mg dose of E5501 2G tablet
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
10-mg dose of E5501 cyclodextrin oral solution
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
10-mg dose of E5501 lipid-based oral
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
10-mg dose of E5501-P powder
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
AKR-501, YM-477
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
AMG 531
Amgen
2007 Phase 3 NCT00603642 Japan;
2007 Phase 1/Phase 2 NCT00515203 Australia;Canada;Spain;United States;
2005 Phase 3 NCT00102336 United States;
2005 Phase 3 NCT00102323 France;Netherlands;Spain;United States;
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom;
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Amgen Inc.
2009 - EUCTR2007-000638-37-IE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2004-000172-13-GB Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2004-000172-13-DE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 - EUCTR2004-000172-13-CZ Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 - EUCTR2004-000172-13-BE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 - EUCTR2004-000172-13-AT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2007 Phase 3 EUCTR2006-003700-18-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 Phase 3 EUCTR2006-003700-18-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 Phase 3 EUCTR2006-003700-18-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2007-003569-42-ES Spain;
2007 - EUCTR2006-003700-18-PT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
AMG531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2004-000172-13-IT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
ARGX-113
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
argenx
2017 Phase 2 NCT03102593 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
argenx BV
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Acetominofene
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Acetominophen
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Alemtuzumab, Rituximab
Hospital Universitario Dr. Jose E. Gonzalez
2008 Phase 2/Phase 3 NCT00749112 Mexico;
All-Trans Retinoid Acid(ATRA)
Shandong University
2013 Phase 3 NCT01882127 China;
Aminophylline
Department of Hematology, The First Affiliated Hospital of Soochow University
2017 - ChiCTR-ONC-17013230 China;
Amoxicillin hydrate
Takeda
2015 - NCT03219723 Japan;
Anti-CD40L
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States;
Anti-CD40LdAb
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States;
Anti-D
University of Aarhus
2004 Phase 2 NCT00128882 Denmark;
Atorvastatin
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China;
Avatrombopag
Eisai Inc.
2012 Phase 3 NCT01433978 United States;
Institute of Hematology & Blood Diseases Hospital
2021 - NCT04890041 China;
Shandong University
2021 - NCT04949009 China;
Avatrombopag (proposed)
Eisai Limited
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
Avatrombopag maleate
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Avatrombopag tablets
Eisai Inc.
2007 Phase 2 NCT00441090 United States;
Azathioprine
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China;
BMS-986004
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States;
BMS-986004 1500 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 225 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 675 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 75 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BT595
Biotest
2016 Phase 3 NCT02859909 Bulgaria;Czechia;Germany;Hungary;Serbia;Spain;
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
Blinded (Avatrombopoag tablets)
Eisai Inc.
2007 Phase 2 NCT00625443 United States;
Blisibimod
Anthera Pharmaceuticals
2015 Phase 2/Phase 3 NCT01609452 -
Bortezomib
Shandong University
2018 Phase 3 NCT03443570 China;
Caffeic acid tablets
Shandong University
2015 Phase 4 NCT02556814 China;
Clarithromycin
Takeda
2015 - NCT03219723 Japan;
Conventional
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt;
Corticosteroids (Aprednislon)
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria;
CsA
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Cyclosporin A
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China;
Cyclosporine
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China;
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China;
DIFENIDRAMINA CLORIDRATO
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Danazol
Second Affiliated Hospital of Dalian Medical University
2018 - ChiCTR1800016177 China;
Decitabine
Shandong University
2018 Phase 3 NCT03252457 China;
Dexamethasone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of;
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy;
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China;
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy;
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China;
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 Japan;
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China;
2021 Phase 2 NCT05023915 China;
2019 Phase 4 NCT03998982 China;
2018 Phase 3 NCT03252457 China;
2015 Phase 4 NCT02556814 China;
2013 Phase 3 NCT01882127 China;
2012 Phase 3 NCT01734057 China;
2012 Phase 3 NCT01734044 China;
2010 Phase 4 NCT01356511 China;
University Hospital, Macau
2015 - ChiCTR1900021211 China;
Dexamethasone (1 cycle)
Shandong University
2015 Phase 4 NCT02642380 China;
Dexamethasone (4 cycles)
Shandong University
2015 Phase 4 NCT02642380 China;
Dexamethasone Abcur
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia;
Dexamethasone and Rituximab
Copenhagen University Hospital at Herlev
2004 Phase 3 NCT00909077 Denmark;
Diammonium glycyrrhizinate enteric-coated capsule
Shandong University
2021 Phase 2 NCT05023915 China;
Doptelet 20 mg film-coated tablets
Dova Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE Czechia;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
Sobi, Inc.
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
Doxil
Hematology and Oncology Specialists
2001 Phase 2 NCT00107913 United States;
Dyphenhydramine hydrochloride
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
E5501
Eisai Inc.
2011 Phase 1 NCT01437384 United States;
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
E5501 40 mg 2 x 20-mg tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands;
E5501 40 mg 2 x 20-mg tablets, orally, with food
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands;
E5501 40mg 2 x 20-mg tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands;
ELTROMBOPAG OLAMINE
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy;
Efgartigimod
ARGENX BV
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom;
argenx
2020 Phase 3 NCT04274452 United States;
2020 Phase 3 NCT04225156 Austria;Belgium;Bulgaria;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT04188379 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BV
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Efgartigimod PH20 SC
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
argenx
2021 Phase 3 NCT04812925 Australia;Japan;Russian Federation;United States;
2020 Phase 3 NCT04687072 Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
Efgartigimod alfa
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
Gandini Domenica
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United State;
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Efgartigimod alpha
argenx BVBA
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Eltrombopag
Eisai Inc.
2012 Phase 3 NCT01433978 United States;
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
GlaxoSmithKline
2012 Phase 3 NCT01520909 Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2009 Phase 2 NCT00908037 Canada;France;Netherlands;Spain;United Kingdom;United States;
2007 Phase 2 NCT00424177 Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States;
2006 Phase 3 NCT00370331 Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom;
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States;
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom;
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom;
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom;
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam;
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 Phase 2 NCT02402998 Italy;
2016 - NCT02298075 Italy;
Humanity & Health Medical Group Limited
2018 Phase 2 NCT03830749 Hong Kong;
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria;
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt;
Novartis Pharmaceuticals
2010 - NCT01416311 -
Peking University People's Hospital
2020 - NCT04214951 China;
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China;
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
University Hospital, Macau
2015 - ChiCTR1900021211 China;
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States;
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China;
Eltrombopag (Revolade)
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy;
Eltrombopag (Revolade®)
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland;
Eltrombopag combining rituximab
Institute of Hematology & Blood Diseases Hospital
2020 Phase 4 NCT04518475 China;
Eltrombopag olamine (SB-497115-GR)
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
Eltrombopag olamine, Revolade, Promacta
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Eltrombopag oral tablets
GlaxoSmithKline
2008 Phase 3 NCT00828750 Japan;
Eltrombopag plus diacerein
Qilu Hospital of Shandong University
2020 Phase 2 NCT04917679 China;
FCM
Shandong University
2016 - NCT02967328 China;
GMA161
Genzyme, a Sanofi Company
2005 Phase 1 NCT00244257 United States;
GNR-069
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation;
Gammaplex
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States;
Gammaplex, intravenous immunoglobulin
Bio Products Laboratory
2007 Phase 3 NCT00504075 Argentina;India;United States;
Glycyrrhetinic Acid
Shandong University
2019 Phase 4 NCT03998982 China;
HBM9161 Dose A
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China;
HBM9161 Dose B
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China;
HMPL-523
Hutchison Medipharma Limited
2021 Phase 3 NCT05029635 -
HUMAN NORMAL IMMUNOGLOBULIN (IV)
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
HUMAX-CD38
Ostfold Hospital Trust
2020 Phase 2 EUCTR2019-004683-22-NO Norway;
Hetrombopag
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 3 NCT04737850 China;
Hetrombopag Olamine
Jiangsu HengRui Medicine Co., Ltd.
2017 Phase 3 NCT03222843 China;
2015 Phase 1 NCT02614846 China;
2014 Phase 1 NCT02403440 China;
High dose Dexamethasone pulses
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of;
Huaiqihuang Granule
Qidong Gaitianli Medicines Co., Ltd
2017 Phase 4 NCT03201848 China;
Human Immunoglobulin
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany;
Human Normal Immunoglobulin (iv)
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
Human Normal Immunoglobulin G (IgG > purity)
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey;
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey;
Human normal immunoglobulin
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland;
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland;
Human normal immunoglobulin for intravenous use
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine;
Hydroxychloroquine
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China;
I10E
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
IGIV3I Grifols
Grifols Biologicals Inc.
2008 Phase 3 NCT00511147 Canada;India;Puerto Rico;United States;
IMMUNOGLOBULIN G
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland;
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland;
Octapharma AG
2013 - EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
IVIG-L
Sanquin
2001 Phase 3 NCT00151840 Poland;
Ig VENA 100 ml vial
Kedrion SpA
2013 - EUCTR2013-000961-36-IT Italy;
Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy;
IgG Next Generation
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
IgNextGen
CSL Limited
2007 Phase 3 NCT00362349 Australia;
Immune Globulin Intravenous (Human), Triple Virally Reduced Solution
Baxalta now part of Shire
2003 Phase 2 NCT00162006 Czech Republic;Czechia;Germany;Hungary;Poland;
Immunglobulin
Octapharma AG
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
Inactivated Trivalent Influenza vaccine
Neufeld, Ellis J, MD, PhD
2004 - NCT01713855 United States;
LIV-GAMMA SN Inj.
SK Plasma Co., Ltd.
2016 Phase 3 NCT03164915 Korea, Republic of;
Lansoprazole, clarithromycin, amoxycillin
Mahidol University
2006 Phase 4 NCT00467571 Thailand;
MabThera
Rikshospitalet
2008 - EUCTR2005-005918-20-FR France;Sweden;United Kingdom;
Medical Standard of Care for ITP
Amgen
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Methylprednisolone
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
2016 Phase 4 study ChiCTR-IIR-16008994 China;
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Metronidazole
Takeda
2015 - NCT03219723 Japan;
Montelukast
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China;
NPLATE 500 microgramos polvo para solución inyectable
Amgen Inc
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom;
Nanogam
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands;
NewGAM
Octapharma AG
2013 - EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
NewGam
Octapharma
2011 Phase 3 NCT01349790 Germany;
Nplate
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation;
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom;
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Octagam
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland;
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland;
Octapharma
2006 Phase 3 NCT00426270 Austria;
Octapharma AG
2006 - EUCTR2005-003552-35-CZ Czech Republic;France;Germany;
Octagam®
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany;
2006 - EUCTR2005-003552-35-DE Czech Republic;France;Germany;
2006 - EUCTR2005-003552-35-AT Austria;Czech Republic;France;Germany;
Open Label (Avatrombopag tablets)
Eisai Inc.
2007 Phase 2 NCT00625443 United States;
Orelabrutinib
Shandong University
2021 Phase 2 NCT05020288 -
Orelabrutinib( higher dose)
Beijing InnoCare Pharma Tech Co., Ltd.
2022 Phase 2 NCT05232149 China;
Orelabrutinib( lower dose)
Beijing InnoCare Pharma Tech Co., Ltd.
2022 Phase 2 NCT05232149 China;
PF-06755347 intravenous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;United Kingdom;United States;
PF-06755347 subcutaneous ITP
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;United Kingdom;United States;
PF-06755347 subcutaneous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;United Kingdom;United States;
PF-06835375
Pfizer
2022 Phase 2 NCT05070845 Poland;United States;
Pfizer Inc.
2022 Phase 2 EUCTR2021-002897-19-HU Australia;Canada;Czechia;Hungary;Poland;United States;
PG2
PhytoHealth Corporation
2008 Phase 2 NCT00860600 Taiwan;
PRTX-100 (Staphylococcal protein A)
Protalex, Inc.
2007 Phase 1 NCT00571467 Australia;New Zealand;
Palmitate
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 Japan;
Placebo
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205351 Japan, Asia except Japan, North America, Europe;
Prednisolone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of;
Prednisone
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy;
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of;
Shandong University
2010 Phase 4 NCT01356511 China;
Privigen®
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey;
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey;
Proteína recombinante estimulante de la megacariopoyesis
Amgen Inc.
2007 - EUCTR2007-003569-42-ES Spain;
R788
Kissei Pharmaceutical Co., Ltd.
2019 Phase 3 NCT04132050 Japan;
REVOLADE, PROMACTA
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States;
Glaxosmithkline Research and Development Ltd
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Recombinant Human Thrombopoietin
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
Recombinant Human Thrombopoietin (rhTPO)
Shandong University
2014 Phase 3 NCT02139501 China;
Recombinant human thrombopoietin (rh-TPO)
Peking University People's Hospital
2020 - NCT04214951 China;
Recombinant human thrombopoietin (rhTPO)
Shandong University
2012 Phase 3 NCT01734057 China;
2012 Phase 3 NCT01734044 China;
2011 Phase 3 NCT01525836 China;
Relovade
GlaxoSmithKline Research and Development Ltd
2013 - EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Revolade
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy;
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy;
GlaxoSmithKline Research and Development Limited
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
GlaxoSmithKline Research and Development Ltd
2014 - EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Revolade 25 mg film-coated tablets
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Revolade 50 mg film-coated tablets
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
RhTPO
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China;
Peking Union Medical College
2011 Phase 3 NCT01805648 China;
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China;
RhTPO in combination with Rituximab
Ming Hou
2009 Phase 3 NCT01506414 China;
Rituximab
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
2019 Phase 4 ChiCTR1900027748 China;
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China;
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy;
Keio University School of Medicine , Yoshitaka miyakawa
2011 Phase 3 JPRN-JMA-IIA00070 Japan;
Neufeld, Ellis J, MD, PhD
2003 Phase 1/Phase 2 NCT01713738 United States;
ROCHE
2005 - EUCTR2005-000859-15-IT Italy;
Shandong University
2018 Phase 3 NCT03443570 China;
2012 Phase 3 NCT01734057 China;
2011 Phase 3 NCT01525836 China;
2010 Phase 4 NCT03258866 China;
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia;
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
Weill Medical College of Cornell University
2004 Phase 2 NCT00161564 United States;
Rituximab [MabThera/Rituxan]
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia;
Romiplostim
Amgen
2012 Phase 3 NCT01444417 Australia;Canada;United States;
2010 Phase 2 NCT01143038 Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2009 Phase 4 NCT00907478 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States;
2009 Phase 3 NCT01071954 Australia;Canada;Spain;United States;
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2005 Phase 3 NCT00508820 Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States;
2004 Phase 3 NCT00116688 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2002 Phase 2 NCT00111475 -
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom;
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Amgen Inc.
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.
2015 Phase 3 NCT02868099 China;
University Hospital, Basel, Switzerland
2016 Phase 4 NCT02760251 Switzerland;
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States;
Romiplostin
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 - NCT02298075 Italy;
Rozanolixizumab
Sugihara Kazuhiro
2021 Phase 3 JPRN-jRCT2031210245 Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Poland;Republic of Moldova;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
UCB Biopharma SRL
2020 Phase 3 NCT04596995 Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;
2020 Phase 3 NCT04224688 Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04200456 Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205351 Japan, Asia except Japan, North America, Europe;
SB-497115
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom;
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States;
GlaxoSmithKline Research and Development Ltd
2014 - EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom;
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Glaxosmithkline Research and Development Ltd
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
SB-497115-GR
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan;
GlaxoSmithKline Research and Development Limited
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
SB497115
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy;
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy;
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom;
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom;
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam;
SM101
SuppreMol GmbH
2010 Phase 1;Phase 2 EUCTR2009-014842-28-BE Belgium;Germany;Poland;
SM101 20mg/mL
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine;
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine;
SM101 5mg/mL
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine;
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine;
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States;
Department of Hematology, Xiniao Hospital
2017 - ChiCTR-ONC-17012126 China;
Standard of care
Eisai Inc.
2012 Phase 3 NCT01433978 United States;
Standard therapy (without eltrombopag): HD-DXM
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland;
Steroids
Safaa AA Khaled
2019 - NCT04113915 -
TAK-079
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Millennium Pharmaceuticals, Inc. (Takeda)
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;Croatia;Germany;Slovenia;Ukraine;United States;
2020 Phase 2 EUCTR2019-004103-12-HR Croatia;Slovenia;Ukraine;United States;
Takeda
2020 Phase 2 NCT04278924 Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Takeda Development Center Americas, Inc. (Takeda)
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
TPO
Shenyang Sunshine Pharmaceutical Co., LTD.
2016 Phase 4 NCT04089267 China;
Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication)
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-JapicCTI-153003 -
Triple therapy
Safaa AA Khaled
2019 - NCT04113915 -
Tysabri
Sahlgrenska University Hospital
2009 - EUCTR2008-005871-92-SE Sweden;
UCB7665
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02718716 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
UCB Biopharma SPRL
2017 Phase 2 EUCTR2015-003984-12-LT Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2017 Phase 2 EUCTR2015-003984-12-BG Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-PL Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-ES Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-DE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-BE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
UCB Biopharma SRL
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003984-12-IT Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
Vonoprazan
Takeda
2015 - NCT03219723 Japan;
Water
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
10-mg dose of E5501 cyclodextrin oral solution
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
10-mg dose of E5501 lipid-based oral
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
10-mg dose of E5501-P powder
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom;
AKR-501, YM-477
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
AMG 531
Amgen
2007 Phase 3 NCT00603642 Japan;
2007 Phase 1/Phase 2 NCT00515203 Australia;Canada;Spain;United States;
2005 Phase 3 NCT00102336 United States;
2005 Phase 3 NCT00102323 France;Netherlands;Spain;United States;
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom;
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Amgen Inc.
2009 - EUCTR2007-000638-37-IE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 3 EUCTR2004-000172-13-GB Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2004-000172-13-DE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 - EUCTR2004-000172-13-CZ Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 - EUCTR2004-000172-13-BE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2008 - EUCTR2004-000172-13-AT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
2007 Phase 3 EUCTR2006-003700-18-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 Phase 3 EUCTR2006-003700-18-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 Phase 3 EUCTR2006-003700-18-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2007-003569-42-ES Spain;
2007 - EUCTR2006-003700-18-PT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-003700-18-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
AMG531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2004-000172-13-IT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
ARGX-113
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
2017 Phase 2 EUCTR2016-003038-26-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
argenx
2017 Phase 2 NCT03102593 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
argenx BV
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Acetominofene
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Acetominophen
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Alemtuzumab, Rituximab
Hospital Universitario Dr. Jose E. Gonzalez
2008 Phase 2/Phase 3 NCT00749112 Mexico;
All-Trans Retinoid Acid(ATRA)
Shandong University
2013 Phase 3 NCT01882127 China;
Aminophylline
Department of Hematology, The First Affiliated Hospital of Soochow University
2017 - ChiCTR-ONC-17013230 China;
Amoxicillin hydrate
Takeda
2015 - NCT03219723 Japan;
Anti-CD40L
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States;
Anti-CD40LdAb
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States;
Anti-D
University of Aarhus
2004 Phase 2 NCT00128882 Denmark;
Atorvastatin
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China;
Avatrombopag
Eisai Inc.
2012 Phase 3 NCT01433978 United States;
Institute of Hematology & Blood Diseases Hospital
2021 - NCT04890041 China;
Shandong University
2021 - NCT04949009 China;
Avatrombopag (proposed)
Eisai Limited
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
Avatrombopag maleate
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Avatrombopag tablets
Eisai Inc.
2007 Phase 2 NCT00441090 United States;
Azathioprine
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China;
BMS-986004
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States;
BMS-986004 1500 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 225 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 675 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 75 mg IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BT595
Biotest
2016 Phase 3 NCT02859909 Bulgaria;Czechia;Germany;Hungary;Serbia;Spain;
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
Blinded (Avatrombopoag tablets)
Eisai Inc.
2007 Phase 2 NCT00625443 United States;
Blisibimod
Anthera Pharmaceuticals
2015 Phase 2/Phase 3 NCT01609452 -
Bortezomib
Shandong University
2018 Phase 3 NCT03443570 China;
Caffeic acid tablets
Shandong University
2015 Phase 4 NCT02556814 China;
Clarithromycin
Takeda
2015 - NCT03219723 Japan;
Conventional
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt;
Corticosteroids (Aprednislon)
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria;
CsA
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Cyclosporin A
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China;
Cyclosporine
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China;
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China;
DIFENIDRAMINA CLORIDRATO
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Danazol
Second Affiliated Hospital of Dalian Medical University
2018 - ChiCTR1800016177 China;
Decitabine
Shandong University
2018 Phase 3 NCT03252457 China;
Dexamethasone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of;
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy;
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China;
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy;
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China;
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 Japan;
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China;
2021 Phase 2 NCT05023915 China;
2019 Phase 4 NCT03998982 China;
2018 Phase 3 NCT03252457 China;
2015 Phase 4 NCT02556814 China;
2013 Phase 3 NCT01882127 China;
2012 Phase 3 NCT01734057 China;
2012 Phase 3 NCT01734044 China;
2010 Phase 4 NCT01356511 China;
University Hospital, Macau
2015 - ChiCTR1900021211 China;
Dexamethasone (1 cycle)
Shandong University
2015 Phase 4 NCT02642380 China;
Dexamethasone (4 cycles)
Shandong University
2015 Phase 4 NCT02642380 China;
Dexamethasone Abcur
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia;
Dexamethasone and Rituximab
Copenhagen University Hospital at Herlev
2004 Phase 3 NCT00909077 Denmark;
Diammonium glycyrrhizinate enteric-coated capsule
Shandong University
2021 Phase 2 NCT05023915 China;
Doptelet 20 mg film-coated tablets
Dova Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE Czechia;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
Sobi, Inc.
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
Doxil
Hematology and Oncology Specialists
2001 Phase 2 NCT00107913 United States;
Dyphenhydramine hydrochloride
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
E5501
Eisai Inc.
2011 Phase 1 NCT01437384 United States;
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
E5501 40 mg 2 x 20-mg tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands;
E5501 40 mg 2 x 20-mg tablets, orally, with food
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands;
E5501 40mg 2 x 20-mg tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands;
ELTROMBOPAG OLAMINE
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy;
Efgartigimod
ARGENX BV
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom;
argenx
2020 Phase 3 NCT04274452 United States;
2020 Phase 3 NCT04225156 Austria;Belgium;Bulgaria;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT04188379 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BV
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Efgartigimod PH20 SC
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
argenx
2021 Phase 3 NCT04812925 Australia;Japan;Russian Federation;United States;
2020 Phase 3 NCT04687072 Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
Efgartigimod alfa
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
Gandini Domenica
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United State;
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Efgartigimod alpha
argenx BVBA
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Eltrombopag
Eisai Inc.
2012 Phase 3 NCT01433978 United States;
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
GlaxoSmithKline
2012 Phase 3 NCT01520909 Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2009 Phase 2 NCT00908037 Canada;France;Netherlands;Spain;United Kingdom;United States;
2007 Phase 2 NCT00424177 Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States;
2006 Phase 3 NCT00370331 Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom;
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States;
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom;
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom;
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom;
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam;
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 Phase 2 NCT02402998 Italy;
2016 - NCT02298075 Italy;
Humanity & Health Medical Group Limited
2018 Phase 2 NCT03830749 Hong Kong;
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria;
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt;
Novartis Pharmaceuticals
2010 - NCT01416311 -
Peking University People's Hospital
2020 - NCT04214951 China;
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China;
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
University Hospital, Macau
2015 - ChiCTR1900021211 China;
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States;
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China;
Eltrombopag (Revolade)
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy;
Eltrombopag (Revolade®)
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland;
Eltrombopag combining rituximab
Institute of Hematology & Blood Diseases Hospital
2020 Phase 4 NCT04518475 China;
Eltrombopag olamine (SB-497115-GR)
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
Eltrombopag olamine, Revolade, Promacta
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Eltrombopag oral tablets
GlaxoSmithKline
2008 Phase 3 NCT00828750 Japan;
Eltrombopag plus diacerein
Qilu Hospital of Shandong University
2020 Phase 2 NCT04917679 China;
FCM
Shandong University
2016 - NCT02967328 China;
GMA161
Genzyme, a Sanofi Company
2005 Phase 1 NCT00244257 United States;
GNR-069
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation;
Gammaplex
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States;
Gammaplex, intravenous immunoglobulin
Bio Products Laboratory
2007 Phase 3 NCT00504075 Argentina;India;United States;
Glycyrrhetinic Acid
Shandong University
2019 Phase 4 NCT03998982 China;
HBM9161 Dose A
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China;
HBM9161 Dose B
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China;
HMPL-523
Hutchison Medipharma Limited
2021 Phase 3 NCT05029635 -
HUMAN NORMAL IMMUNOGLOBULIN (IV)
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
HUMAX-CD38
Ostfold Hospital Trust
2020 Phase 2 EUCTR2019-004683-22-NO Norway;
Hetrombopag
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 3 NCT04737850 China;
Hetrombopag Olamine
Jiangsu HengRui Medicine Co., Ltd.
2017 Phase 3 NCT03222843 China;
2015 Phase 1 NCT02614846 China;
2014 Phase 1 NCT02403440 China;
High dose Dexamethasone pulses
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of;
Huaiqihuang Granule
Qidong Gaitianli Medicines Co., Ltd
2017 Phase 4 NCT03201848 China;
Human Immunoglobulin
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany;
Human Normal Immunoglobulin (iv)
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
Human Normal Immunoglobulin G (IgG > purity)
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey;
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey;
Human normal immunoglobulin
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland;
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland;
Human normal immunoglobulin for intravenous use
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine;
Hydroxychloroquine
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China;
I10E
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
IGIV3I Grifols
Grifols Biologicals Inc.
2008 Phase 3 NCT00511147 Canada;India;Puerto Rico;United States;
IMMUNOGLOBULIN G
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland;
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland;
Octapharma AG
2013 - EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
IVIG-L
Sanquin
2001 Phase 3 NCT00151840 Poland;
Ig VENA 100 ml vial
Kedrion SpA
2013 - EUCTR2013-000961-36-IT Italy;
Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy;
IgG Next Generation
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain;
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain;
IgNextGen
CSL Limited
2007 Phase 3 NCT00362349 Australia;
Immune Globulin Intravenous (Human), Triple Virally Reduced Solution
Baxalta now part of Shire
2003 Phase 2 NCT00162006 Czech Republic;Czechia;Germany;Hungary;Poland;
Immunglobulin
Octapharma AG
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
Inactivated Trivalent Influenza vaccine
Neufeld, Ellis J, MD, PhD
2004 - NCT01713855 United States;
LIV-GAMMA SN Inj.
SK Plasma Co., Ltd.
2016 Phase 3 NCT03164915 Korea, Republic of;
Lansoprazole, clarithromycin, amoxycillin
Mahidol University
2006 Phase 4 NCT00467571 Thailand;
MabThera
Rikshospitalet
2008 - EUCTR2005-005918-20-FR France;Sweden;United Kingdom;
Medical Standard of Care for ITP
Amgen
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Methylprednisolone
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
2016 Phase 4 study ChiCTR-IIR-16008994 China;
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Metronidazole
Takeda
2015 - NCT03219723 Japan;
Montelukast
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China;
NPLATE 500 microgramos polvo para solución inyectable
Amgen Inc
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom;
Nanogam
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands;
NewGAM
Octapharma AG
2013 - EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
NewGam
Octapharma
2011 Phase 3 NCT01349790 Germany;
Nplate
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation;
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom;
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Octagam
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland;
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland;
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland;
Octapharma
2006 Phase 3 NCT00426270 Austria;
Octapharma AG
2006 - EUCTR2005-003552-35-CZ Czech Republic;France;Germany;
Octagam®
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany;
2006 - EUCTR2005-003552-35-DE Czech Republic;France;Germany;
2006 - EUCTR2005-003552-35-AT Austria;Czech Republic;France;Germany;
Open Label (Avatrombopag tablets)
Eisai Inc.
2007 Phase 2 NCT00625443 United States;
Orelabrutinib
Shandong University
2021 Phase 2 NCT05020288 -
Orelabrutinib( higher dose)
Beijing InnoCare Pharma Tech Co., Ltd.
2022 Phase 2 NCT05232149 China;
Orelabrutinib( lower dose)
Beijing InnoCare Pharma Tech Co., Ltd.
2022 Phase 2 NCT05232149 China;
PF-06755347 intravenous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;United Kingdom;United States;
PF-06755347 subcutaneous ITP
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;United Kingdom;United States;
PF-06755347 subcutaneous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;United Kingdom;United States;
PF-06835375
Pfizer
2022 Phase 2 NCT05070845 Poland;United States;
Pfizer Inc.
2022 Phase 2 EUCTR2021-002897-19-HU Australia;Canada;Czechia;Hungary;Poland;United States;
PG2
PhytoHealth Corporation
2008 Phase 2 NCT00860600 Taiwan;
PRTX-100 (Staphylococcal protein A)
Protalex, Inc.
2007 Phase 1 NCT00571467 Australia;New Zealand;
Palmitate
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 Japan;
Placebo
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205351 Japan, Asia except Japan, North America, Europe;
Prednisolone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of;
Prednisone
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy;
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of;
Shandong University
2010 Phase 4 NCT01356511 China;
Privigen®
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey;
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey;
Proteína recombinante estimulante de la megacariopoyesis
Amgen Inc.
2007 - EUCTR2007-003569-42-ES Spain;
R788
Kissei Pharmaceutical Co., Ltd.
2019 Phase 3 NCT04132050 Japan;
REVOLADE, PROMACTA
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States;
Glaxosmithkline Research and Development Ltd
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Recombinant Human Thrombopoietin
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
Recombinant Human Thrombopoietin (rhTPO)
Shandong University
2014 Phase 3 NCT02139501 China;
Recombinant human thrombopoietin (rh-TPO)
Peking University People's Hospital
2020 - NCT04214951 China;
Recombinant human thrombopoietin (rhTPO)
Shandong University
2012 Phase 3 NCT01734057 China;
2012 Phase 3 NCT01734044 China;
2011 Phase 3 NCT01525836 China;
Relovade
GlaxoSmithKline Research and Development Ltd
2013 - EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Revolade
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy;
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy;
GlaxoSmithKline Research and Development Limited
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
GlaxoSmithKline Research and Development Ltd
2014 - EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Revolade 25 mg film-coated tablets
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Revolade 50 mg film-coated tablets
Eisai Limited
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
RhTPO
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China;
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China;
Peking Union Medical College
2011 Phase 3 NCT01805648 China;
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China;
RhTPO in combination with Rituximab
Ming Hou
2009 Phase 3 NCT01506414 China;
Rituximab
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
2019 Phase 4 ChiCTR1900027748 China;
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China;
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy;
Keio University School of Medicine , Yoshitaka miyakawa
2011 Phase 3 JPRN-JMA-IIA00070 Japan;
Neufeld, Ellis J, MD, PhD
2003 Phase 1/Phase 2 NCT01713738 United States;
ROCHE
2005 - EUCTR2005-000859-15-IT Italy;
Shandong University
2018 Phase 3 NCT03443570 China;
2012 Phase 3 NCT01734057 China;
2011 Phase 3 NCT01525836 China;
2010 Phase 4 NCT03258866 China;
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia;
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China;
Weill Medical College of Cornell University
2004 Phase 2 NCT00161564 United States;
Rituximab [MabThera/Rituxan]
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia;
Romiplostim
Amgen
2012 Phase 3 NCT01444417 Australia;Canada;United States;
2010 Phase 2 NCT01143038 Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2009 Phase 4 NCT00907478 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States;
2009 Phase 3 NCT01071954 Australia;Canada;Spain;United States;
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2005 Phase 3 NCT00508820 Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States;
2004 Phase 3 NCT00116688 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2002 Phase 2 NCT00111475 -
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom;
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Amgen Inc.
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.
2015 Phase 3 NCT02868099 China;
University Hospital, Basel, Switzerland
2016 Phase 4 NCT02760251 Switzerland;
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States;
Romiplostin
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 - NCT02298075 Italy;
Rozanolixizumab
Sugihara Kazuhiro
2021 Phase 3 JPRN-jRCT2031210245 Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Poland;Republic of Moldova;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
UCB Biopharma SRL
2020 Phase 3 NCT04596995 Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;
2020 Phase 3 NCT04224688 Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 NCT04200456 Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205351 Japan, Asia except Japan, North America, Europe;
SB-497115
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom;
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States;
GlaxoSmithKline Research and Development Ltd
2014 - EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
2013 - EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom;
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Glaxosmithkline Research and Development Ltd
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
SB-497115-GR
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan;
GlaxoSmithKline Research and Development Limited
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
SB497115
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy;
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy;
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy;
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom;
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom;
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom;
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam;
SM101
SuppreMol GmbH
2010 Phase 1;Phase 2 EUCTR2009-014842-28-BE Belgium;Germany;Poland;
SM101 20mg/mL
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine;
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine;
SM101 5mg/mL
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine;
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine;
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States;
Department of Hematology, Xiniao Hospital
2017 - ChiCTR-ONC-17012126 China;
Standard of care
Eisai Inc.
2012 Phase 3 NCT01433978 United States;
Standard therapy (without eltrombopag): HD-DXM
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland;
Steroids
Safaa AA Khaled
2019 - NCT04113915 -
TAK-079
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Millennium Pharmaceuticals, Inc. (Takeda)
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;Croatia;Germany;Slovenia;Ukraine;United States;
2020 Phase 2 EUCTR2019-004103-12-HR Croatia;Slovenia;Ukraine;United States;
Takeda
2020 Phase 2 NCT04278924 Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Takeda Development Center Americas, Inc. (Takeda)
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
TPO
Shenyang Sunshine Pharmaceutical Co., LTD.
2016 Phase 4 NCT04089267 China;
Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication)
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-JapicCTI-153003 -
Triple therapy
Safaa AA Khaled
2019 - NCT04113915 -
Tysabri
Sahlgrenska University Hospital
2009 - EUCTR2008-005871-92-SE Sweden;
UCB7665
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02718716 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
UCB Biopharma SPRL
2017 Phase 2 EUCTR2015-003984-12-LT Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2017 Phase 2 EUCTR2015-003984-12-BG Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-PL Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-ES Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-DE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2015-003984-12-BE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
UCB Biopharma SRL
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003984-12-IT Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
Vonoprazan
Takeda
2015 - NCT03219723 Japan;
Water
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China;